Market research
IDH.LSE Immunodiagnostic Systems Holdings PLC
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 109M
- P/E ratio
- 290.77
- Analyst target
- 268.59
- Dividend yield
- 0.5%
- Beta
- 0.92
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- GB00B01YZ052
- Market cap
- 109M
- P/E ratio
- 290.77
- Analyst target
- 268.59
- Dividend yield
- 0.5%
- Beta
- 0.92
About
About Immunodiagnostic Systems Holdings PLC
Immunodiagnostic Systems Holdings PLC develops, manufactures, and sells in-vitro diagnostic tests to the clinical laboratory market in the United Kingdom, the United States, Germany, France, and internationally. It develops, manufactures, and markets immunoassays and automated immunoanalyser technologies to provide diagnostic outcomes for patients. It offers IDS-iSYS multi-discipline automated systems, which is based on chemiluminescence and absorbency technology is used for immunoassay testing. The company provides its products and services for diagnosis of bone metabolism, calcium metabolism, hypertension, chronic kidney disease mineral bone disorder, growth, fertility, autoimmunity, infectious disease, sarcoidosis, and allergy. Immunodiagnostic Systems Holdings PLC was founded in 1977 and is headquartered in Boldon, the United Kingdom. As of July 12, 2021, Immunodiagnostic Systems Holdings PLC operates as a subsidiary of PerkinElmer (UK) Holdings Limited.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the IDH.LSE discussion.
5 years, 5 months ago
Immunodiagnostic Systems Holdings PLC is currently in a long term uptrend where the price is trading 52.8% above its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.6.
Immunodiagnostic Systems Holdings PLC's total revenue sank by 0.0% to $9M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $8K since the same quarter in the previous year.
Finally, its free cash flow fell by 193.4% to $-710K since the same quarter in the previous year.
Based on the above factors, Immunodiagnostic Systems Holdings PLC gets an overall score of 2/5.